Download PDF
Semin Neurol 2017; 37(02): 135-146
DOI: 10.1055/s-0037-1601567
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Genetic Forms of Parkinson's Disease

Christine Y. Kim
2   Department of Movement Disorders, Columbia University Medical Center, New York, New York
,
Roy N. Alcalay
1   Department of Neurology, Columbia University Medical Center, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
16 May 2017 (online)

   Permissions and Reprints

Abstract

One of the greatest advances in Parkinson's disease (PD) research in the past two decades has been a better understanding of PD genetics. Of the many candidate genes investigated, the best studied include LRRK2, SNCA, VPS35, Parkin, PINK1, and DJ1. The authors review the key clinical features of these monogenic forms, as well as for the prevalent risk factor gene, GBA, including the phenotype, clinical course, and treatment response. They also outline areas for future investigation: longitudinal studies of PD's clinical course, the identification of its premotor manifestations, and its specific mechanisms of pathogenicity.

Keywords

Parkinson's disease - genetics - LRRK2 - SNCA - VPS35 - Parkin - PINK1 - DJ1 - GBA
 

  • References

  • 1 Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18 (R1): R48-R59
    CrossrefPubMedGoogle Scholar
  • 2 Wszolek ZK, Pfeiffer B, Fulgham JR , et al. Western Nebraska family (family D) with autosomal dominant parkinsonism. Neurology 1995; 45 (3 Pt 1): 502-505
    CrossrefPubMedGoogle Scholar
  • 3 Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51 (3) 296-301
    CrossrefPubMedGoogle Scholar
  • 4 Zimprich A, Biskup S, Leitner P , et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44 (4) 601-607
    CrossrefPubMedGoogle Scholar
  • 5 Paisán-Ruíz C, Jain S, Evans EW , et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44 (4) 595-600
    CrossrefPubMedGoogle Scholar
  • 6 Rosenbusch KE, Kortholt A. Activation mechanism of LRRK2 and its cellular functions in Parkinson's disease. Parkinsons Dis 2016; 2016: 7351985
    PubMedGoogle Scholar
  • 7 West AB, Cookson MR. Identification of bona-fide LRRK2 kinase substrates. Mov Disord 2016; 31 (8) 1140-1141
    CrossrefPubMedGoogle Scholar
  • 8 Pankratz N, Pauciulo MW, Elsaesser VE , et al; Parkinson Study Group-PROGENI Investigators. Mutations in LRRK2 other than G2019S are rare in a North American-based sample of familial Parkinson's disease. Mov Disord 2006; 21 (12) 2257-2260
    CrossrefPubMedGoogle Scholar
  • 9 Gorostidi A, Ruiz-Martínez J, Lopez de Munain A, Alzualde A, Martí Massó JF. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 2009; 10 (2) 157-159
    CrossrefPubMedGoogle Scholar
  • 10 Funayama M, Hasegawa K, Ohta E , et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005; 57 (6) 918-921
    CrossrefPubMedGoogle Scholar
  • 11 Lu CS, Simons EJ, Wu-Chou YH , et al. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism Relat Disord 2005; 11 (8) 521-522
    CrossrefPubMedGoogle Scholar
  • 12 Funayama M, Li Y, Tomiyama H , et al. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 2007; 18 (3) 273-275
    CrossrefPubMedGoogle Scholar
  • 13 Kim JM, Lee JY, Kim HJ , et al. The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population. Parkinsonism Relat Disord 2010; 16 (2) 85-88
    CrossrefPubMedGoogle Scholar
  • 14 Di Fonzo A, Wu-Chou YH, Lu CS , et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 2006; 7 (3) 133-138
    CrossrefPubMedGoogle Scholar
  • 15 Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 2006; 6: 47
    CrossrefPubMedGoogle Scholar
  • 16 Chan DK, Ng PW, Mok V , et al. LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with early-onset Parkinson's disease compared to late-onset patients. J Neural Transm (Vienna) 2008; 115 (9) 1275-1277
    CrossrefPubMedGoogle Scholar
  • 17 An XK, Peng R, Li T , et al. LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. Eur J Neurol 2008; 15 (3) 301-305
    CrossrefPubMedGoogle Scholar
  • 18 Marras C, Alcalay RN, Caspell-Garcia C , et al; LRRK2 Cohort Consortium. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease. Mov Disord 2016; 31 (8) 1192-1202
    CrossrefPubMedGoogle Scholar
  • 19 Aasly JO, Toft M, Fernandez-Mata I , et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005; 57 (5) 762-765
    CrossrefPubMedGoogle Scholar
  • 20 Di Fonzo A, Rohé CF, Ferreira J , et al; Italian Parkinson Genetics Network. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005; 365 (9457): 412-415
    PubMedGoogle Scholar
  • 21 Healy DG, Falchi M, O'Sullivan SS , et al; International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7 (7) 583-590
    CrossrefPubMedGoogle Scholar
  • 22 Tan EK, Shen H, Tan LC , et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett 2005; 384 (3) 327-329
    CrossrefPubMedGoogle Scholar
  • 23 Marder K, Wang Y, Alcalay RN , et al; LRRK2 Ashkenazi Jewish Consortium. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology 2015; 85 (1) 89-95
    CrossrefPubMedGoogle Scholar
  • 24 Alcalay RN, Mejia-Santana H, Tang MX , et al. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol 2009; 66 (12) 1517-1522
    PubMedGoogle Scholar
  • 25 Nabli F, Ben Sassi S, Amouri R, Duda JE, Farrer MJ, Hentati F. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study. Mov Disord 2015; 30 (2) 253-258
    CrossrefPubMedGoogle Scholar
  • 26 Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol 2005; 57 (6) 933-934
    CrossrefPubMedGoogle Scholar
  • 27 Gilks WP, Abou-Sleiman PM, Gandhi S , et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365 (9457): 415-416
    PubMedGoogle Scholar
  • 28 Ben Sassi S, Nabli F, Hentati E , et al. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (3) 243-246
    CrossrefPubMedGoogle Scholar
  • 29 Alcalay RN, Mejia-Santana H, Mirelman A , et al; LRRK2 Ashkenazi Jewish Consortium. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. Parkinsonism Relat Disord 2015; 21 (2) 106-110
    CrossrefPubMedGoogle Scholar
  • 30 Marras C, Schüle B, Munhoz RP , et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011; 77 (4) 325-333
    CrossrefPubMedGoogle Scholar
  • 31 Saunders-Pullman R, Stanley K, San Luciano M , et al. Gender differences in the risk of familial parkinsonism: beyond LRRK2?. Neurosci Lett 2011; 496 (2) 125-128
    CrossrefPubMedGoogle Scholar
  • 32 Saunders-Pullman R, Mirelman A, Wang C , et al. Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?. Ann Clin Transl Neurol 2014; 1 (9) 670-678
    CrossrefPubMedGoogle Scholar
  • 33 Saunders-Pullman R, Alcalay RN, Mirelman A , et al; AJ LRRK2 Consortium. REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers. Mov Disord 2015; 30 (13) 1834-1839
    CrossrefPubMedGoogle Scholar
  • 34 Saunders-Pullman R, Barrett MJ, Stanley KM , et al. LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord 2010; 25 (15) 2536-2541
    CrossrefPubMedGoogle Scholar
  • 35 Inzelberg R, Cohen OS, Aharon-Peretz J , et al. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology 2012; 78 (11) 781-786
    CrossrefPubMedGoogle Scholar
  • 36 Saunders-Pullman R, Stanley K, Wang C , et al. Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology 2011; 77 (4) 319-324
    CrossrefPubMedGoogle Scholar
  • 37 Mirelman A, Alcalay RN, Saunders-Pullman R , et al; LRRK2 AJ consortium. Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene. Mov Disord 2015; 30 (7) 981-986
    CrossrefPubMedGoogle Scholar
  • 38 Mirelman A, Bernad-Elazari H, Thaler A , et al. Arm swing as a potential new prodromal marker of Parkinson's disease. Mov Disord 2016; 31 (10) 1527-1534
    CrossrefPubMedGoogle Scholar
  • 39 Shanker V, Groves M, Heiman G , et al. Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease. Mov Disord 2011; 26 (10) 1875-1880
    CrossrefPubMedGoogle Scholar
  • 40 Poulopoulos M, Cortes E, Vonsattel JP , et al. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J Mol Neurosci 2012; 47 (1) 139-143
    CrossrefPubMedGoogle Scholar
  • 41 Kalia LV, Lang AE, Hazrati LN , et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 2015; 72 (1) 100-105
    CrossrefPubMedGoogle Scholar
  • 42 Polymeropoulos MH, Higgins JJ, Golbe LI , et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996; 274 (5290): 1197-1199
    CrossrefPubMedGoogle Scholar
  • 43 Polymeropoulos MH, Lavedan C, Leroy E , et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276 (5321): 2045-2047
    CrossrefPubMedGoogle Scholar
  • 44 Chan P, Tanner CM, Jiang X, Langston JW. Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. Neurology 1998; 50 (2) 513-514
    CrossrefPubMedGoogle Scholar
  • 45 Scott WK, Yamaoka LH, Stajich JM , et al. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics 1999; 2 (3) 191-192
    CrossrefPubMedGoogle Scholar
  • 46 Zarranz JJ, Alegre J, Gómez-Esteban JC , et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55 (2) 164-173
    CrossrefPubMedGoogle Scholar
  • 47 Krüger R, Kuhn W, Müller T , et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18 (2) 106-108
    CrossrefPubMedGoogle Scholar
  • 48 Proukakis C, Dudzik CG, Brier T , et al. A novel α-synuclein missense mutation in Parkinson disease. Neurology 2013; 80 (11) 1062-1064
    CrossrefPubMedGoogle Scholar
  • 49 Lesage S, Anheim M, Letournel F , et al; French Parkinson's Disease Genetics Study Group. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 2013; 73 (4) 459-471
    CrossrefPubMedGoogle Scholar
  • 50 Kasten M, Klein C. The many faces of alpha-synuclein mutations. Mov Disord 2013; 28 (6) 697-701
    CrossrefPubMedGoogle Scholar
  • 51 Chartier-Harlin MC, Kachergus J, Roumier C , et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364 (9440): 1167-1169
    CrossrefPubMedGoogle Scholar
  • 52 Papadimitriou D, Antonelou R, Miligkos M , et al. Motor and nonmotor features of carriers of the p.A53T alpha-synuclein mutation: a longitudinal study. Mov Disord 2016; 31 (8) 1226-1230
    CrossrefPubMedGoogle Scholar
  • 53 Singleton AB, Farrer M, Johnson J , et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302 (5646): 841
    CrossrefPubMedGoogle Scholar
  • 54 Nishioka K, Ross OA, Ishii K , et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord 2009; 24 (12) 1811-1819
    CrossrefPubMedGoogle Scholar
  • 55 Ahn TB, Kim SY, Kim JY , et al. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008; 70 (1) 43-49
    CrossrefPubMedGoogle Scholar
  • 56 Ibáñez P, Bonnet AM, Débarges B , et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364 (9440): 1169-1171
    CrossrefPubMedGoogle Scholar
  • 57 Vilariño-Güell C, Wider C, Ross OA , et al. VPS35 mutations in Parkinson disease. Am J Hum Genet 2011; 89 (1) 162-167
    CrossrefPubMedGoogle Scholar
  • 58 Zimprich A, Benet-Pagès A, Struhal W , et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011; 89 (1) 168-175
    CrossrefPubMedGoogle Scholar
  • 59 Guella I, Soldà G, Cilia R , et al. The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson's disease. Mov Disord 2012; 27 (6) 800-801
    CrossrefPubMedGoogle Scholar
  • 60 Lesage S, Condroyer C, Klebe S , et al; French Parkinson's Disease Genetics Study Group. Identification of VPS35 mutations replicated in French families with Parkinson disease. Neurology 2012; 78 (18) 1449-1450
    CrossrefPubMedGoogle Scholar
  • 61 Ando M, Funayama M, Li Y , et al. VPS35 mutation in Japanese patients with typical Parkinson's disease. Mov Disord 2012; 27 (11) 1413-1417
    CrossrefPubMedGoogle Scholar
  • 62 Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 Japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 1996; 47 (1) 160-166
    CrossrefPubMedGoogle Scholar
  • 63 Matsumine H, Saito M, Shimoda-Matsubayashi S , et al. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet 1997; 60 (3) 588-596
    PubMedGoogle Scholar
  • 64 Kitada T, Asakawa S, Hattori N , et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392 (6676): 605-608
    CrossrefPubMedGoogle Scholar
  • 65 Hattori N, Kitada T, Matsumine H , et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 1998; 44 (6) 935-941
    CrossrefPubMedGoogle Scholar
  • 66 Jeon BS, Kim JM, Lee DS, Hattori N, Mizuno Y. An apparently sporadic case with parkin gene mutation in a Korean woman. Arch Neurol 2001; 58 (6) 988-989
    CrossrefPubMedGoogle Scholar
  • 67 Lücking CB, Abbas N, Dürr A , et al; The European Consortium on Genetic Susceptibility in Parkinson's Disease and the French Parkinson's Disease Genetics Study Group. Homozygous deletions in parkin gene in European and North African families with autosomal recessive juvenile parkinsonism. Lancet 1998; 352 (9137): 1355-1356
    CrossrefPubMedGoogle Scholar
  • 68 Hedrich K, Marder K, Harris J , et al. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology 2002; 58 (8) 1239-1246
    CrossrefPubMedGoogle Scholar
  • 69 Marder KS, Tang MX, Mejia-Santana H , et al. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol 2010; 67 (6) 731-738
    PubMedGoogle Scholar
  • 70 Li X, Gehring K. Structural studies of parkin and sacsin: mitochondrial dynamics in neurodegenerative diseases. Mov Disord 2015; 30 (12) 1610-1619
    CrossrefPubMedGoogle Scholar
  • 71 Rub C, Wilkening A, Voos W. Mitochondrial quality control by the Pink1/Parkin system. Cell Tissue Res 2017; 367 (1) 111-123
    CrossrefPubMedGoogle Scholar
  • 72 Kilarski LL, Pearson JP, Newsway V , et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord 2012; 27 (12) 1522-1529
    CrossrefPubMedGoogle Scholar
  • 73 Hedrich K, Eskelson C, Wilmot B , et al. Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord 2004; 19 (10) 1146-1157
    CrossrefPubMedGoogle Scholar
  • 74 Klein C, Schumacher K, Jacobs H , et al. Association studies of Parkinson's disease and parkin polymorphisms. Ann Neurol 2000; 48 (1) 126-127
    PubMedGoogle Scholar
  • 75 Deng H, Le WD, Hunter CB , et al. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol 2006; 63 (2) 273-277
    CrossrefPubMedGoogle Scholar
  • 76 Kann M, Hedrich K, Vieregge P , et al. The parkin gene is not involved in late-onset Parkinson's disease. Neurology 2002; 58 (5) 835 , author reply 835
    PubMedGoogle Scholar
  • 77 Oliveira SA, Scott WK, Martin ER , et al. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol 2003; 53 (5) 624-629
    CrossrefPubMedGoogle Scholar
  • 78 Klein C, Hedrich K, Wellenbrock C , et al. Frequency of parkin mutations in late-onset Parkinson's disease. Ann Neurol 2003; 54 (3) 415-416 , author reply 416–417
    PubMedGoogle Scholar
  • 79 Khan NL, Brooks DJ, Pavese N , et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002; 125 (Pt 10): 2248-2256
    CrossrefPubMedGoogle Scholar
  • 80 Lohmann E, Thobois S, Lesage S , et al; French Parkinson's Disease Genetics Study Group. A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology 2009; 72 (2) 110-116
    CrossrefPubMedGoogle Scholar
  • 81 Caccappolo E, Alcalay RN, Mejia-Santana H , et al. Neuropsychological profile of Parkin mutation carriers with and without Parkinson disease: the CORE-PD Study. J Int Neuropsychol Soc 2011; 17 (1) 91-100
    CrossrefPubMedGoogle Scholar
  • 82 Alcalay RN, Caccappolo E, Mejia-Santana H , et al. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol 2014; 71 (1) 62-67
    CrossrefPubMedGoogle Scholar
  • 83 Khan NL, Katzenschlager R, Watt H , et al. Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 2004; 62 (7) 1224-1226
    CrossrefPubMedGoogle Scholar
  • 84 Alcalay RN, Siderowf A, Ottman R , et al. Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology 2011; 76 (4) 319-326
    CrossrefPubMedGoogle Scholar
  • 85 Morgante F, Fasano A, Ginevrino M , et al. Impulsive-compulsive behaviors in parkin-associated Parkinson disease. Neurology 2016; 87 (14) 1436-1441
    CrossrefPubMedGoogle Scholar
  • 86 Cesari R, Martin ES, Calin GA , et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A 2003; 100 (10) 5956-5961
    CrossrefPubMedGoogle Scholar
  • 87 Fujiwara M, Marusawa H, Wang HQ , et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene 2008; 27 (46) 6002-6011
    CrossrefPubMedGoogle Scholar
  • 88 Poulogiannis G, McIntyre RE, Dimitriadi M , et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A 2010; 107 (34) 15145-15150
    CrossrefPubMedGoogle Scholar
  • 89 Veeriah S, Taylor BS, Meng S , et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet 2010; 42 (1) 77-82
    CrossrefPubMedGoogle Scholar
  • 90 Alcalay RN, Clark LN, Marder KS, Bradley WE. Lack of association between cancer history and PARKIN genotype: a family based study in PARKIN/Parkinson's families. Genes Chromosomes Cancer 2012; 51 (12) 1109-1113
    CrossrefPubMedGoogle Scholar
  • 91 Kay DM, Moran D, Moses L , et al. Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol 2007; 61 (1) 47-54
    CrossrefPubMedGoogle Scholar
  • 92 Kay DM, Stevens CF, Hamza TH , et al. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 2010; 75 (13) 1189-1194
    CrossrefPubMedGoogle Scholar
  • 93 Pankratz N, Kissell DK, Pauciulo MW , et al; Parkinson Study Group-PROGENI Investigators. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology 2009; 73 (4) 279-286
    CrossrefPubMedGoogle Scholar
  • 94 Romito LM, Contarino MF, Ghezzi D, Franzini A, Garavaglia B, Albanese A. High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease. J Neurol 2005; 252 (2) 208-211
    CrossrefPubMedGoogle Scholar
  • 95 Moro E, Volkmann J, König IR , et al. Bilateral subthalamic stimulation in Parkin and PINK1 parkinsonism. Neurology 2008; 70 (14) 1186-1191
    CrossrefPubMedGoogle Scholar
  • 96 Angeli A, Mencacci NE, Duran R , et al. Genotype and phenotype in Parkinson's disease: lessons in heterogeneity from deep brain stimulation. Mov Disord 2013; 28 (10) 1370-1375
    CrossrefPubMedGoogle Scholar
  • 97 Pramstaller PP, Schlossmacher MG, Jacques TS , et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 2005; 58 (3) 411-422
    CrossrefPubMedGoogle Scholar
  • 98 Doherty KM, Silveira-Moriyama L, Parkkinen L , et al. Parkin disease: a clinicopathologic entity?. JAMA Neurol 2013; 70 (5) 571-579
    CrossrefPubMedGoogle Scholar
  • 99 Valente EM, Bentivoglio AR, Dixon PH , et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001; 68 (4) 895-900
    CrossrefPubMedGoogle Scholar
  • 100 Valente EM, Abou-Sleiman PM, Caputo V , et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304 (5674): 1158-1160
    CrossrefPubMedGoogle Scholar
  • 101 Valente EM, Salvi S, Ialongo T , et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56 (3) 336-341
    CrossrefPubMedGoogle Scholar
  • 102 Rogaeva E, Johnson J, Lang AE , et al. Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol 2004; 61 (12) 1898-1904
    CrossrefPubMedGoogle Scholar
  • 103 Ibáñez P, Lesage S, Lohmann E , et al; French Parkinson's Disease Genetics Study Group. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 2006; 129 (Pt 3): 686-694
    CrossrefPubMedGoogle Scholar
  • 104 Hatano Y, Sato K, Elibol B , et al. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 2004; 63 (8) 1482-1485
    CrossrefPubMedGoogle Scholar
  • 105 Bonifati V, Rohé CF, Breedveld GJ , et al; Italian Parkinson Genetics Network. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 2005; 65 (1) 87-95
    CrossrefPubMedGoogle Scholar
  • 106 Truban D, Hou X, Caulfield TR, Fiesel FC, Springer W. PINK1, Parkin, and mitochondrial quality control: what can we learn about Parkinson's disease pathobiology?. J Parkinsons Dis 2017; 7 (1) 13-29
    PubMedGoogle Scholar
  • 107 Bentivoglio AR, Cortelli P, Valente EM , et al. Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Mov Disord 2001; 16 (6) 999-1006
    CrossrefPubMedGoogle Scholar
  • 108 Ephraty L, Porat O, Israeli D , et al. Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov Disord 2007; 22 (4) 566-569
    CrossrefPubMedGoogle Scholar
  • 109 Ferraris A, Ialongo T, Passali GC , et al. Olfactory dysfunction in parkinsonism caused by PINK1 mutations. Mov Disord 2009; 24 (16) 2350-2357
    PubMedGoogle Scholar
  • 110 Abou-Sleiman PM, Muqit MM, McDonald NQ , et al. A heterozygous effect for PINK1 mutations in Parkinson's disease?. Ann Neurol 2006; 60 (4) 414-419
    CrossrefPubMedGoogle Scholar
  • 111 Kasten M, Weichert C, Lohmann K, Klein C. Clinical and demographic characteristics of PINK1 mutation carriers--a meta-analysis. Mov Disord 2010; 25 (7) 952-954
    CrossrefPubMedGoogle Scholar
  • 112 Samaranch L, Lorenzo-Betancor O, Arbelo JM , et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010; 133 (Pt 4): 1128-1142
    CrossrefPubMedGoogle Scholar
  • 113 Takanashi M, Li Y, Hattori N. Absence of Lewy pathology associated with PINK1 homozygous mutation. Neurology 2016; 86 (23) 2212-2213
    CrossrefPubMedGoogle Scholar
  • 114 van Duijn CM, Dekker MC, Bonifati V , et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001; 69 (3) 629-634
    CrossrefPubMedGoogle Scholar
  • 115 Bonifati V, Rizzu P, van Baren MJ , et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299 (5604): 256-259
    CrossrefPubMedGoogle Scholar
  • 116 Sironi F, Primignani P, Ricca S , et al. DJ1 analysis in a large cohort of Italian early onset Parkinson disease patients. Neurosci Lett 2013; 557 (Pt B): 165-170
    CrossrefPubMedGoogle Scholar
  • 117 Alcalay RN, Caccappolo E, Mejia-Santana H , et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol 2010; 67 (9) 1116-1122
    PubMedGoogle Scholar
  • 118 Maraganore DM, Wilkes K, Lesnick TG , et al. A limited role for DJ1 in Parkinson disease susceptibility. Neurology 2004; 63 (3) 550-553
    CrossrefPubMedGoogle Scholar
  • 119 Neudorfer O, Giladi N, Elstein D , et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996; 89 (9) 691-694
    CrossrefPubMedGoogle Scholar
  • 120 Aharon-Peretz J, Badarny S, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology 2005; 65 (9) 1460-1461
    CrossrefPubMedGoogle Scholar
  • 121 Beavan MS, Schapira AH. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 2013; 45 (8) 511-521
    CrossrefPubMedGoogle Scholar
  • 122 Alcalay RN, Levy OA, Waters CC , et al. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain 2015; 138 (Pt 9): 2648-2658
    CrossrefPubMedGoogle Scholar
  • 123 Huang CL, Wu-Chou YH, Lai SC , et al. Contribution of glucocerebrosidase mutation in a large cohort of sporadic Parkinson's disease in Taiwan. Eur J Neurol 2011; 18 (10) 1227-1232
    CrossrefPubMedGoogle Scholar
  • 124 Wu YR, Chen CM, Chao CY , et al. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry 2007; 78 (9) 977-979
    CrossrefPubMedGoogle Scholar
  • 125 Lesage S, Anheim M, Condroyer C , et al; French Parkinson's Disease Genetics Study Group. Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 2011; 20 (1) 202-210
    CrossrefPubMedGoogle Scholar
  • 126 Neumann J, Bras J, Deas E , et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132 (Pt 7): 1783-1794
    CrossrefPubMedGoogle Scholar
  • 127 Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351 (19) 1972-1977
    CrossrefPubMedGoogle Scholar
  • 128 Sidransky E, Nalls MA, Aasly JO , et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361 (17) 1651-1661
    CrossrefPubMedGoogle Scholar
  • 129 Gan-Or Z, Giladi N, Rozovski U , et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008; 70 (24) 2277-2283
    CrossrefPubMedGoogle Scholar
  • 130 Anheim M, Elbaz A, Lesage S , et al; French Parkinson Disease Genetic Group. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012; 78 (6) 417-420
    CrossrefPubMedGoogle Scholar
  • 131 Alcalay RN, Dinur T, Quinn T , et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol 2014; 71 (6) 752-757
    CrossrefPubMedGoogle Scholar
  • 132 Gan-Or Z, Amshalom I, Kilarski LL , et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 2015; 84 (9) 880-887
    CrossrefPubMedGoogle Scholar
  • 133 Brockmann K, Srulijes K, Pflederer S , et al. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord 2015; 30 (3) 407-411
    CrossrefPubMedGoogle Scholar
  • 134 Oeda T, Umemura A, Mori Y , et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiol Aging 2015; 36 (12) 3306-3313
    CrossrefPubMedGoogle Scholar
  • 135 Alcalay RN, Caccappolo E, Mejia-Santana H , et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012; 78 (18) 1434-1440
    CrossrefPubMedGoogle Scholar
  • 136 Brockmann K, Srulijes K, Hauser AK , et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011; 77 (3) 276-280
    CrossrefPubMedGoogle Scholar
  • 137 Gan-Or Z, Mirelman A, Postuma RB , et al. GBA mutations are associated with rapid eye movement sleep behavior disorder. Ann Clin Transl Neurol 2015; 2 (9) 941-945
    CrossrefPubMedGoogle Scholar
  • 138 Cilia R, Tunesi S, Marotta G , et al. Survival and dementia in GBA-associated Parkinson's disease: the mutation matters. Ann Neurol 2016; 80 (5) 662-673
    CrossrefPubMedGoogle Scholar
  • 139 Thaler A, Gurevich T, Bar Shira A , et al. A “dose” effect of mutations in the GBA gene on Parkinson's disease phenotype. Parkinsonism Relat Disord 2016; S1353-8020(16)30495-3
    PubMedGoogle Scholar
  • 140 Clark LN, Kartsaklis LA, Wolf Gilbert R , et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009; 66 (5) 578-583
    CrossrefPubMedGoogle Scholar
  • 141 Parkkinen L, Neumann J, O'Sullivan SS , et al. Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. Mol Genet Metab 2011; 103 (4) 410-412
    CrossrefPubMedGoogle Scholar
  • 142 Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E. Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathol 2010; 120 (5) 641-649
    CrossrefPubMedGoogle Scholar
  • 143 Funayama M, Ohe K, Amo T , et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurol 2015; 14 (3) 274-282
    CrossrefPubMedGoogle Scholar
  • 144 Foo JN, Liu J, Tan EK. CHCHD2 and Parkinson's disease. Lancet Neurol 2015; 14 (7) 681-682
    CrossrefPubMedGoogle Scholar
  • 145 Koschmidder E, Weissbach A, Brüggemann N, Kasten M, Klein C, Lohmann K. A nonsense mutation in CHCHD2 in a patient with Parkinson disease. Neurology 2016; 86 (6) 577-579
    CrossrefPubMedGoogle Scholar
  • 146 Gagliardi M, Iannello G, Colica C, Annesi G, Quattrone A. Analysis of CHCHD2 gene in familial Parkinson's disease from Calabria. Neurobiol Aging 2017; 50: 169.e5-169.e6
    CrossrefPubMedGoogle Scholar
  • 147 Tejera-Parrado C, Jesús S, Huertas-Fernández I , et al. Genetic analysis of CHCHD2 in a southern Spanish population. Neurobiol Aging 2017; 50: 169.e1-169.e2
    CrossrefPubMedGoogle Scholar
  • 148 Fan TS, Lin HI, Lin CH, Wu RM. Lack of CHCHD2 mutations in Parkinson's disease in a Taiwanese population. Neurobiol Aging 2016; 38: 218.e1-218.e2
    CrossrefPubMedGoogle Scholar
  • 149 Li NN, Wang L, Tan EK , et al. Genetic analysis of CHCHD2 gene in Chinese Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2016; 171 (8) 1148-1152
    CrossrefPubMedGoogle Scholar
  • 150 Yang X, Zhao Q, An R , et al. Mutational scanning of the CHCHD2 gene in Han Chinese patients with Parkinson's disease and meta-analysis of the literature. Parkinsonism Relat Disord 2016; 29: 42-46
    CrossrefPubMedGoogle Scholar
  • 151 Deng HX, Shi Y, Yang Y , et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet 2016; 48 (7) 733-739
    CrossrefPubMedGoogle Scholar
  • 152 Yan W, Tang B, Zhou X , et al. TMEM230 mutation analysis in Parkinson's disease in a Chinese population. Neurobiol Aging 2017; 49: 219.e1-219.e3
    CrossrefPubMedGoogle Scholar
  • 153 Giri A, Mok KY, Jansen I , et al; International Parkinson's Disease Consortium (IPDGC). Lack of evidence for a role of genetic variation in TMEM230 in the risk for Parkinson's disease in the Caucasian population. Neurobiol Aging 2017; 50: 167.e11-167.e13
    CrossrefPubMedGoogle Scholar
  • 154 Sudhaman S, Muthane UB, Behari M, Govindappa ST, Juyal RC, Thelma BK. Evidence of mutations in RIC3 acetylcholine receptor chaperone as a novel cause of autosomal-dominant Parkinson's disease with non-motor phenotypes. J Med Genet 2016; 53 (8) 559-566
    CrossrefPubMedGoogle Scholar
  • 155 Gan-Or Z, Ozelius LJ, Bar-Shira A , et al. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 2013; 80 (17) 1606-1610
    CrossrefPubMedGoogle Scholar
  • 156 Foo JN, Liany H, Bei JX , et al. Rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson's disease. Neurobiol Aging 2013; 34 (12) 2890.e13-2890.e15
    CrossrefPubMedGoogle Scholar
  • 157 Dagan E, Adir V, Schlesinger I , et al. SMPD1 mutations and Parkinson disease. Parkinsonism Relat Disord 2015; 21 (10) 1296-1297
    CrossrefPubMedGoogle Scholar
  • 158 Gan-Or Z, Orr-Urtreger A, Alcalay RN, Bressman S, Giladi N, Rouleau GA. The emerging role of SMPD1 mutations in Parkinson's disease: implications for future studies. Parkinsonism Relat Disord 2015; 21 (10) 1294-1295
    CrossrefPubMedGoogle Scholar
  • 159 Vilariño-Güell C, Rajput A, Milnerwood AJ , et al. DNAJC13 mutations in Parkinson disease. Hum Mol Genet 2014; 23 (7) 1794-1801
    CrossrefPubMedGoogle Scholar
  • 160 Gibb WR, Narabayashi H, Yokochi M, Iizuka R, Lees AJ. New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology 1991; 41 (6) 820-822
    CrossrefPubMedGoogle Scholar
  • 161 Guella I, Sherman HE, Appel-Cresswell S, Rajput A, Rajput AH, Farrer MJ. Parkinsonism in GTP cyclohydrolase 1 mutation carriers. Brain 2015; 138 (Pt 5): e349
    CrossrefPubMedGoogle Scholar
  • 162 Mok KY, Sheerin U, Simón-Sánchez J , et al; International Parkinson's Disease Genomics Consortium (IPDGC). Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurol 2016; 15 (6) 585-596
    CrossrefPubMedGoogle Scholar
  • 163 Butcher NJ, Kiehl TR, Hazrati LN , et al. Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol 2013; 70 (11) 1359-1366
    CrossrefPubMedGoogle Scholar
  • 164 Köroğlu Ç, Baysal L, Cetinkaya M, Karasoy H, Tolun A. DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat Disord 2013; 19 (3) 320-324
    CrossrefPubMedGoogle Scholar
  • 165 Edvardson S, Cinnamon Y, Ta-Shma A , et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One 2012; 7 (5) e36458
    CrossrefPubMedGoogle Scholar
  • 166 Elsayed LE, Drouet V, Usenko T , et al. A novel nonsense mutation in DNAJC6 expands the phenotype of autosomal-recessive juvenile-onset Parkinson's disease. Ann Neurol 2016; 79 (2) 335-337
    PubMedGoogle Scholar
  • 167 Olgiati S, Quadri M, Fang M , et al; International Parkinsonism Genetics Network. DNAJC6 mutations associated with early-onset Parkinson's disease. Ann Neurol 2016; 79 (2) 244-256
    CrossrefPubMedGoogle Scholar
  • 168 Najim al-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M. Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 1994; 89 (5) 347-352
    PubMedGoogle Scholar
  • 169 Park JS, Blair NF, Sue CM. The role of ATP13A2 in Parkinson's disease: clinical phenotypes and molecular mechanisms. Mov Disord 2015; 30 (6) 770-779
    CrossrefPubMedGoogle Scholar
  • 170 Lesage S, Drouet V, Majounie E , et al; French Parkinson's Disease Genetics Study (PDG); International Parkinson's Disease Genomics Consortium (IPDGC). Loss of VPS13C function in autosomal-recessive parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin-dependent mitophagy. Am J Hum Genet 2016; 98 (3) 500-513
    CrossrefPubMedGoogle Scholar
  • 171 Quadri M, Fang M, Picillo M , et al; International Parkinsonism Genetics Network. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum Mutat 2013; 34 (9) 1208-1215
    CrossrefPubMedGoogle Scholar
  • 172 Di Fonzo A, Dekker MC, Montagna P , et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009; 72 (3) 240-245
    CrossrefPubMedGoogle Scholar
  • 173 Lohmann E, Coquel AS, Honoré A , et al. A new F-box protein 7 gene mutation causing typical Parkinson's disease. Mov Disord 2015; 30 (8) 1130-1133
    CrossrefPubMedGoogle Scholar
  • 174 Malaguti MC, Melzi V, Di Giacopo R , et al. A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism. Parkinsonism Relat Disord 2015; 21 (3) 337-339
    CrossrefPubMedGoogle Scholar
  • 175 Wilson GR, Sim JC, McLean C , et al. Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology. Am J Hum Genet 2014; 95 (6) 729-735
    CrossrefPubMedGoogle Scholar
  • 176 Mata IF, Jang Y, Kim CH , et al. The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. Mol Neurodegener 2015; 10: 50
    CrossrefPubMedGoogle Scholar
  • 177 Lesage S, Bras J, Cormier-Dequaire F , et al; French Parkinson's Disease Genetics Study Group (PDG) and the International Parkinson's Disease Genomics Consortium (IPDGC). Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson disease. Neurol Genet 2015; 1 (1) e9
    CrossrefPubMedGoogle Scholar